Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

43.12 1.27 −2.86%
Market cap
$3.6B
P/E
29.9×
Fwd P/E
45.1×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
8 8 8 8

+8 more TTM periods

ROE
8.77% 6.93% 5.34% 2.49%
ROA
8.09% 6.40% 4.90% 2.29%
ROIC
7.32% 5.35% 4.03% 1.74%
Return on Tangible Assets
21.44% 18.01% 14.72% 7.66%
Average Days of Receivables
35.19 33.76 31.52 35.26
Free Cash Flow per Share
2.08 1.95 1.61 1.25
Free Cash Flow
165.99 155.34 126.63 98.21
Capital Expenditures
(12.39) (10.82) (9.68) (10.04)
Other line items
Cash ROIC
8.86% 8.71% 7.35% 6.05%
Accounts Receivable Turnover
10.70 10.43 11.34 10.25
Accounts Payable Turnover
16.33 13.93 23.38 20.53
Inventory Turnover
6.67 6.90 7.31 7.66
Average Days of Payables
18.43 16.00 10.84 12.90
Days of Inventory on Hand
52.03 49.61 48.50 47.61
Tax Rate
(0.01) (0.03) (0.03) (0.02)
Research and Development Expense of Revenue
16.62% 14.80% 13.69% 13.99%
Selling, General and Administrative Expense of Revenue
35.88% 37.57% 40.79% 44.31%
Share Based Compensation of Revenue
8.63% 8.38% 8.43% 8.55%
Operating CF/Net income
1.56 1.89 2.05 3.57
Depreciation/Fixed assets
0.83 0.82 0.82 1.03
Capex/Depreciation
(0.68) (0.59) (0.53) (0.52)
Revenue per Share
7.03 6.81 6.58 6.29
Operating CF per Share
2.23 2.09 1.73 1.38
Capex per Share
(0.15) (0.14) (0.12) (0.13)
Capex to Sales
0.02 0.02 0.02 0.02

Fold the line items

Columns are period end dates